CTIS2023-507843-12-01进行中（未招募）1 期
Cannabidiol in refractory childhood epilepsy, a personalized high-quality approach
niversitair Medisch Centrum Utrecht0 个研究点目标入组 50 人开始时间: 2024年4月24日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 17（—）
- 性别
- All
入选标准
- •Minimum age of 1 year old and maximum age of 18 years old., Confirmed diagnosis of refractory epilepsy according to ILAE criteria., At least 4 countable seizures (not all on one day) during the 4-week baseline period while receiving at least 1 ASM., All medications or interventions for epilepsy must have been stable dosed for one month prior to screening and the participant is willing to maintain the current ASM regimen throughout the trial., Informed consent/assent of legal representative/ parents., Presence of a consistently available patient caregiver for proxy-reports.
排除标准
- •Any known or suspected hypersensitivity to cannabinoids or any of the excipients of the Investigational Medicinal Product (IMP)., History of recreational or medicinal cannabis, or cannabinoid-based medications, within three months prior to screening and the patient is unwilling to abstain for the duration of the study., Planned intervention under general anesthesia interfering with the baseline period; or any planned major surgery within the duration of the trial., Expected inability to undergo blood sampling due to anxiety or resistance., History or current symptoms of significantly impaired liver function, such as bilirubin level = 2 x upper limit of normal; or presence of liver damage as indicated by levels of alanine aminotransferase and/or aspartate aminotransferase = 3 x upper limit of normal., Pregnancy, breastfeeding, or intention to become pregnant throughout the trial or within 3 months of completing treatment., Structural heart disease., Glaucoma., Ongoing evaluation for epilepsy surgery., Implementation of vagal nerve stimulation within 3 months prior to screening and unwillingness to delay inclusion until stable settings of vagal nerve stimulation are reached., Starting a ketogenic diet within 3 months prior to screening and unwillingness to delay inclusion until a stable ketogenic diet is reached., Unstable medical condition(s), other than refractory epilepsy, that are of significant influence on participation in the trial; significance to be determined with the treating physician/pediatric neurologist.
研究者
相似试验
进行中（未招募）
1 期
Cannabidiol in Children With Refractory Epileptic EncephalopathyEpileptic EncephalopathyNCT03024827University of Saskatchewan20
已完成
3 期
Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)Dravet SyndromeEpilepsyNCT02091375Jazz Pharmaceuticals120
已完成
3 期
GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet SyndromeDravet SyndromeEpilepsyNCT02224703Jazz Pharmaceuticals199
Unknown
不适用
The Use of Medicinal Cannabinoids as Adjunctive Treatment for Medically Refractory EpilepsyEpilepsy, Unspecified, Refractory (Medically)NCT02523183University of Colorado, Denver150
No Longer Available
不适用
Cannabidiol for Pediatric Epilepsy (Compassionate Use)Refractory Childhood EpilepsyNCT02556008University of California, Los Angeles